The U.S. President’s son was instrumental in funding a firm conducting pathogen and anthrax research in Ukrainian biolabs.
An investment firm directed by President Joe Biden’s son Hunter Biden was a leading financial backer of a pandemic tracking and response firm that collaborated on identifying and isolating deadly pathogens in Ukrainian laboratories, receiving funds from the Obama administration’s Department of Defense in the process, The National Pulse can exclusively reveal.
If you want more scoops like this, please consider supporting our work so we can hire more research staff and report on real and important news like this, daily.
Rosemont Seneca Technology Partners (RSTP) – a subsidiary of the Hunter Biden and Christopher Heinz-founded Rosemont Capital – counted both Biden and Heinz as managing directors. Heinz is the stepson of former U.S. Secretary of State and current Climate czar John Kerry.
Amongst the companies listed on archived versions of the RSTP’s portfolio is Metabiota – an ostensibly San Francisco-based company that purports to detect, track, and analyze emerging infectious diseases.
Financial reports reveal that RSTP led the company’s first round of funding in 2015, which amounted to $30 million. Former managing director and co-founder of RSTP Neil Callahan – a name that also appears many times on Hunter Biden’s hard drive – sits on Metabiota’s Board of Advisors alongside former Clinton official Rob Walker who discussed, in another unearthed Hunter Biden hard drive e-mail, reaching out to the Obama Department of Defense with regard to Metabiota.
In July 2021, The National Pulse exclusively revealed the connection between Metabiota, Hunter Biden, and the pandemic-linked EcoHealth Alliance which worked closely with Anthony Fauci’s National Institute for Allergy and Infectious Disease (NIAID) and the notorious Wuhan laboratory.
Today, we can exclusively reveal an official connection between the Biden-linked pandemic firm and biological laboratories based in...
Read More HERE
No comments:
Post a Comment